Free Trial

Immunome (IMNM) Stock Forecast & Price Target

$13.27
-0.04 (-0.30%)
(As of 08:36 AM ET)

Immunome - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Immunome in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for IMNM.

Consensus Price Target

$29.80
124.57% Upside
High Forecast$35.00
Average Forecast$29.80
Low Forecast$24.00

According to the 6 analysts' twelve-month price targets for Immunome, the average price target is $29.80. The highest price target for IMNM is $35.00, while the lowest price target for IMNM is $24.00. The average price target represents a forecasted upside of 124.57% from the current price of $13.27.

TypeCurrent Forecast
7/23/23 to 7/22/24
1 Month Ago
6/23/23 to 6/22/24
3 Months Ago
4/24/23 to 4/23/24
1 Year Ago
7/23/22 to 7/23/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$29.80$29.80$32.67$8.00
Forecasted Upside124.57% Upside83.91% Upside56.20% Upside55.49% Upside
Get Immunome Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.

IMNM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMNM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunome Stock vs. The Competition

TypeImmunomeMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside123.89% Upside2,980.95% Upside10.08% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/31/2024Piper Sandler
2 of 5 stars
B. Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$27.00+83.55%
5/14/2024Wedbush
3 of 5 stars
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00+128.69%
4/30/2024JPMorgan Chase & Co.
3 of 5 stars
 Initiated CoverageOverweight$24.00+73.66%
4/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$35.00+70.07%
1/29/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/29/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$30.00+71.62%
7/10/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
5/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:36 AM ET.

IMNM Forecast - Frequently Asked Questions

What is Immunome's forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunome is $29.80, with a high forecast of $35.00 and a low forecast of $24.00.

Should I buy or sell Immunome stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMNM shares.

Does Immunome's stock price have much upside?

According to analysts, Immunome's stock has a predicted upside of 83.91% based on their 12-month stock forecasts.

What analysts cover Immunome?

Immunome has been rated by research analysts at JPMorgan Chase & Co., Piper Sandler, and Wedbush in the past 90 days.

Do Wall Street analysts like Immunome more than its competitors?

Analysts like Immunome more than other "medical" companies. The consensus rating for Immunome is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMNM compares to other companies.


This page (NASDAQ:IMNM) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners